Ocular Therapeutix, Inc.
NASDAQ:OCULBiotechnology
Healthcare
$5.86 -1.17%
-$0.11 today
- Market cap
- $1.29B
- Beta
- 0.90
- P/E (TTM)
- -7.3
- EPS (TTM)
- -$1.30
52W Low $6.23High $16.44
Volume 3.08M
Average 3.00M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$204.88M
FY 2025 · Annual
Investing Cash Flow
-$11.88M
FY 2025 · Annual
Financing Cash Flow
$561.72M
FY 2025 · Annual
+69.1% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (6.55M) | (71.04M) | (80.74M) | (193.51M) | (265.94M) |
| Depreciation & Amortization | 2.42M | 2.11M | 2.98M | 3.79M | 4.32M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.98M | 16.96M | 17.83M | 33.11M | 43.18M |
| Change in Working Capital | (2.9M) | 1.35M | (7.41M) | (10.23M) | 7.71M |
| Accounts Receivables | (8.88M) | (190K) | (4.85M) | (6.21M) | 1.74M |
| Inventory | (49K) | (724K) | (331K) | (735K) | (524K) |
| Accounts Payables | 1.8M | (621K) | 583K | (318K) | (887K) |
| Other Working Capital | 4.24M | 2.88M | (2.81M) | (2.97M) | 7.38M |
| Other Non-Cash Items | (73.49M) | (8.99M) | (2.9M) | 32.16M | 5.84M |
| Operating Cash Flow | (65.55M) | (59.6M) | (70.23M) | (134.68M) | (204.88M) |
| Capital Expenditures | (1.19M) | (3.72M) | (6.09M) | (1.29M) | (12.01M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 130K |
| Investing Cash Flow | (1.19M) | (3.72M) | (6.09M) | (1.29M) | (11.88M) |
| Debt Repayment | (445K) | 0 | 56.35M | 316.35M | 0 |
| Common Stock Issued | 985K | 940K | 118.11M | 316.35M | 561.72M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.31M | 514K | (4.63M) | (300.6M) | 0 |
| Financing Cash Flow | 2.85M | 1.45M | 169.83M | 332.11M | 561.72M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (63.89M) | (61.86M) | 93.51M | 196.15M | 344.96M |
| Free Cash Flow | (66.74M) | (63.32M) | (76.32M) | (135.97M) | (216.89M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$265.9M
+ D&A$4.3M
+ Stock-Based Comp$43.2M
+ Deferred Tax$0
+ Working Capital$7.7M
+ Other Non-Cash$5.8M
= Operating Cash Flow-$204.9M
- Capex-$12.0M
= Free Cash Flow-$216.9M
Analysis
FY2025 free cash flow is -$216.9M. FCF conversion is 81.6% of net income. Operating cash flow was -$204.9M, with capex of -$12.0M. The largest bridge item is Stock-Based Comp at $43.2M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 10, 2026 | |
| 3 | Initial statement of beneficial ownership | Nov 10, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 |
Does OCUL generate free cash flow?
Ocular Therapeutix, Inc. (OCUL) generated -$216.89M of free cash flow in fiscal 2025.
How much operating cash flow does OCUL produce?
Operating cash flow was -$204.88M, before capital expenditures of $12.01M.
Continue the stock analysis
Jump to another research area for this company.